37th Annual VEITH Symposium
NEW YORK, Nov 17, 2010 (BUSINESS WIRE) —
Covidien (NYSE:COV), a leading global provider of healthcare
products, today announced that results from a prospective,
multicenter study using the
VNUS ClosureFAST(TM) catheter, demonstrated clinical efficacy
and improvement in quality of life for patients. The ClosureFAST
catheter is an endovenous
radiofrequency (RF) ablation catheter designed to heat and
close diseased veins, the major underlying cause of varicose
The results were presented at the American College of
Phlebology’s 24th Annual Congress in Orlando, Florida on
November 5, and here today at the 37th Annual VEITH
Symposium on Vascular and Endovascular Issues.
Alan Dietzek, M.D., Chief of Vascular Surgery and the Linda and
Stephen R. Cohen Chair in Vascular Surgery at Danbury Hospital in
Connecticut, presented three-year follow-up results of patients
treated with the ClosureFAST catheter from a study conducted at 13
centers in the U.S. and Europe. Two-hundred sixty-seven
greater saphenous veins were evaluated at the follow-up and
demonstrated a 93% occlusion rate using Kaplan-Meier analysis.
In addition to clinical efficacy, the study has shown a venous
clinical severity score reduction at three-year follow up, which
indicates an improvement in patients’ relief of symptoms, such as
pain or inflammation, from the baseline score at time of
These results were consistent with those presented this month
for the seven European study sites by Professor Thomas M.
Proebstle, M.D., PhD, of the Department of Dermatology, University
of Mainz, Germany, and the University of PÃ©cs,
Hungary, in his presentation titled, “Three Year Follow-Up After
Radiofrequency Segmental Thermal Ablation of Great Saphenous
Veins.” The European study was presented at the American College of
“These study results continue to support and strengthen
clinicians’ confidence in the ClosureFAST technology and its
effectiveness in treating millions of venous insufficiency patients
who suffer from varicose veins,” said Joe Woody, President,
Vascular Therapies, Covidien.
Covidien is a leading global healthcare products company that
creates innovative medical solutions for better patient outcomes
and delivers value through clinical leadership and excellence.
Covidien manufactures, distributes and services a diverse range of
industry-leading product lines in three segments: Medical Devices,
Pharmaceuticals and Medical Supplies. With 2010 revenue of $10.4
billion, Covidien has approximately 42,000 employees worldwide in
more than 60 countries, and its products are sold in over 140
countries. Please visit
www.covidien.com to learn more about our business.